TA 7906

Drug Profile

TA 7906

Alternative Names: M-5200; TA-7906

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tanabe Seiyaku
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Anti-inflammatories; Skin disorder therapies
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 09 Sep 2015 Phase-II development is ongoing in Japan
  • 30 Jun 2012 Phase-II clinical trials in Atopic dermatitis in Japan (Topical)
  • 29 Oct 2010 Phase-I clinical trials in Atopic dermatitis in Japan (topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top